Ovarian tumors of low malignant potential.

被引：7

作者：

Trimble E.L. ^{[1
,2
]}

Trimble C.L. ^{[2
]}

机构：

[1] National Cancer Institute, Bethesda, MD 20892-7436, 6130 Executive Boulevard, Suite 741

[2] The Johns Hopkins Hospital, Baltimore, MD 21287

来源：

Current Treatment Options in Oncology | 2001年 / 2卷 / 2期

关键词：

Epithelial Ovarian Cancer; Ovarian Tumor; Borderline Tumor; Epithelial Ovarian Carcinoma; Pseudomyxoma Peritonei;

D O I：

10.1007/s11864-001-0052-2

中图分类号：

学科分类号：

摘要：

Ovarian tumors of low malignant potential (LMP) differ from epithelial ovarian carcinoma in etiology, molecular biology, and prognosis. LMP tumors are not precursor lesions to ovarian carcinoma. Treatment is primarily surgical. Women found to have an ovarian tumor of LMP should undergo removal of the involved adnexa; surgical staging; and cytoreductive surgery. Women in the reproductive years should be given the option of conservative surgery, preserving the contralateral adnexa and uterus. There is no proven benefit to adjuvant chemotherapy or radiotherapy after primary surgery. In most cases, the diagnosis of an ovarian tumor of LMP conveys good prognosis, with excellent long-term survival.

引用

页码：103 / 108

页数：5

共 32 条

[1]

Prat J, Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal, Adv Anat Pathol, 6, pp. 247-274, (1999)

[2]

Gershenson DM, Silva EG, Levy L, Ovarian serous borderline tumors with invasive peritoneal implants, Cancer, 82, pp. 1096-1103, (1998)

[3]

Burks RT, Sherman ME, Kurman RJ, Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors, Am J Surg Pathol, 20, pp. 1319-1330, (1996)

[4]

Eichhorn JH, Bell DA, Young RH, Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns, Am J Surg Pathol, 23, pp. 397-409, (1999)

[5]

Dietel M, Hauptmann S, Serous tumors of low malignant potential of the ovary. I. Diagnostic pathology, Virchows Arch, 436, pp. 403-412, (2000)

[6]

Ronnett BM, Shmookler BM, Sugarbaker PH, Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary, Anat Pathol, 2, pp. 197-226, (1997)

[7]

Riopel MA, Ronnett BM, Kurman RJ, Evaluation of diagnostic criteria and behavior of ovarian intestinaltype mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas, Am J Surg Pathol, 23, pp. 617-635, (1999)

[8]

Lawrence WD, The borderland between benign and malignant surface epithelial ovarian tumors. Current controversy over the nature and nomenclature of ’borderline’ ovarian tumors, Cancer, 76, pp. 2138-2142, (1995)

[9]

Gotleib WH, Friedman E, Bar-Sade RB, Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors, J Natl Cancer Inst, 90, pp. 995-1000, (1998)

[10]

Lu KH, Cramer DW, Muto MG, A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer, Obstet Gynecol, 93, pp. 34-37, (1999)

← 1 2 3 4 →